Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Keeps Shopping: Mirus Acquisition Bolsters RNAi Portfolio

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm will pay $125 million for access to Wisconsin-based Mirus’ Dynamic PolyConjugates technology.

You may also be interested in...



Roche's Transfer Of Assets To Arrowhead May Create Most-Comprehensive RNAi Firm

After an expensive foray into RNAi, Roche is handing off its substantial portfolio to Arrowhead, in exchange for a 10% stake in the company and right-of-first-negotiation to programs and earn-out potential.

Roche's Transfer Of Assets To Arrowhead May Create Most-Comprehensive RNAi Firm

After an expensive foray into RNAi, Roche is handing off its substantial portfolio to Arrowhead, in exchange for a 10% stake in the company and right-of-first-negotiation to programs and earn-out potential.

Roche Assures Investors: “Right Moment Is Now” To Acquire Genentech

Roche would consider another Genentech-like deal, but the biotech itself has grown too large and the time is right to bring it in-house, Humer says.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS068124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel